IRVINE, Calif., Jan. 20, 2015 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced the appointment of Karen Warner, RN, as Vice President of Payer Access and Reimbursement. Ms. Warner joined on January 19, 2015 and will be responsible for managed care, payer access, and reimbursement.
"Karen joins CombiMatrix at a very exciting time for the company with the recent additions of new products to our prenatal testing portfolio and our continued sales growth," said Mark McDonough, President and Chief Executive Officer of CombiMatrix. "Karen's expertise in payer relations and reimbursement will be a critical asset as we work to expand coverage of our service offerings across payer types and geographies nationwide."
Ms. Warner has more than 30 years of experience in the healthcare industry. She joins CombiMatrix from Bako Integrated Physician Solutions where she served as Director of Payer Relations and was responsible for national market access for all payers, including Medicare, Medicaid, commercial and other government program and private institution payers. Within 12 months at Bako, she secured direct multi-year national agreements at preferred pricing with six large national payers and 27 key regional/state Blues plans. Prior to Bako, Ms. Warner was president of Touch Point Consulting, a payer relations consulting company in molecular diagnostics, genetics and personalized medicine. Ms. Warner has previously held various positions in payer relations and reimbursement at Genoptix Medical Laboratories, Alkermes and Sanofi-Synthelabo. Ms. Warner is a Registered Nurse and holds a BSN from the University of Bridgeport.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care – specializing in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers comprehensive testing services for the detection of abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. The Company performs genetic testing utilizing microarray, FISH, PCR and G-Band chromosome analyses. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "goal," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," "objective," similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: market acceptance of CMA as a preferred method over karyotyping; the rate of transition to CMA from karyotyping; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in both developmental medicine and oncology; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
CONTACT: Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: Robert Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 email@example.com Media Contact: David Schull or Lena Evans Russo Partners LLC (212) 845-4271 firstname.lastname@example.org email@example.com